JPRN-UMIN000002463
Recruiting
未知
A exploratory study of the efficacy and safety of oxaliplatin in combination with S-1 in the treatment of non-resectable gastric cancer - Oxaliplatin and S-1 therapy for gastric cancer
niversity of Tokyo Hospital0 sites20 target enrollmentSeptember 7, 2009
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- non-resectable gastric cancer or reccurent gastric cancer
- Sponsor
- niversity of Tokyo Hospital
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •history of use of oxaliplatin severe dysfuntion of major organs Hematopoietic disorder sensory neuropathy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
An exploratory study of the efficacy and safety of yokukansan for postoperative delirium in patients who underwent surgical resection of malignant tumor of digestive system.Digestive system cancerJPRN-UMIN000013235Hitachi,Ltd.,Hitachi General Hospital40
Recruiting
Not Applicable
An exploratory study on the efficacy and safety of Hangesyasinto (TJ-14) for DCF chemotherapy or DCF-RT chemoradiotherapy induced diarrhea in the patients with advanced esophageal cancer.JPRN-UMIN000023825Dokkyo Medical University24
Recruiting
Phase 2
An exploratory study of the safety and efficacy of disulfiram in progressive fibrosing interstitial lung diseaseprogressive fibrosing interstitial lung diseaseinterstitial lung diseaseD017563JPRN-jRCTs031220648rushiyama Hirokazu10
Not yet recruiting
Not Applicable
Study on the safety and efficacy of upper extremity motor function recovery after neuromodulatory stimulation using low-intensity focused ultrasound (NS-US200) in patients with ischemic strokeDiseases of the circulatory systemKCT0008320Korea University Anam Hospital12
Active, not recruiting
Not Applicable
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe DiseasePompe disease (acid alpha-glucosidase deficiency)MedDRA version: 17.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2015-000584-14-Outside-EU/EEAGenzyme Corporation Inc4